New PKU drug enters early human testing
NCT ID NCT07241234
First seen Nov 21, 2025 · Last updated May 22, 2026 · Updated 30 times
Summary
This early-stage study tests a new drug called AG-181 in 20 adults with phenylketonuria (PKU), a genetic condition that causes high levels of the amino acid phenylalanine. The main goal is to check the drug's safety and how the body processes it. Participants must have a specific gene mutation and high phenylalanine levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHENYLKETONURIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Texas Southwestern Medical Center (UTSW)
RECRUITINGDallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.